Type III hyperlipoproteinemia unmasked by HIV anti-retroviral therapy [3]

American Journal of Medicine

Volumn 118, Issue 6, 2005, Pages 691-692

  Samaha, Frederick F ^a   Ky, Bonnie ^a   Re III, Vincent Lo ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; CASE REPORT; CHOLESTEROL BLOOD LEVEL; CLINICAL FEATURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPOPROTEINEMIA TYPE 3; LETTER; LIPOPROTEIN BLOOD LEVEL; MALE; MEDICAL EXAMINATION; PRIORITY JOURNAL; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-HIV AGENTS; HUMANS; HYPERLIPOPROTEINEMIAS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RECEPTORS, RETINOIC ACID; TRIGLYCERIDES;

EID: 19544380213     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.03.024     Document Type: Letter

References (5)

1. R.W. Mahley, Y. Huang, S.C. Rall Jr Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia) questions, quandaries, and paradoxes J Lipid Res. 40 1999 1933 1949
2. J.R. Guyton Treatment of type III hyperlipoproteinemia Am Heart J. 138 1999 17 18
3. R.K. Lister, M. Youlse, D.R. Nair, A.F. Winder, M.H.A. Rustin Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors Lancet 363 1999 1678
4. M. Shahmanesh, H. Jaleel, Y. DeSilva, J.D.C. Ross, M. Caslake, R. Cramb Protease inhibitor related type III hyperliporproteinemia is common and not associated with apolipoprotein-E E2/E2 phenotype Sex Transm Infect. 77 2001 283 286
5. A. Carr, K. Samaras, D.J. Chisholm, D.A. Cooper Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance Lancet 351 1998 1881 1883